HPV-16 E6 TCR

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameHPV-16 E6 TCR

Drug Alias NameE6 TCRanti-HPV-16 E6 TCRanti-HPV E6 TCRHPV-16 E6 TCR

ClassificationCell and gene therapy > Cell therapy > Donor > AutologousCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > TCR therapy

Mechanisms of ActionGene transferenceProtein E6 modulators

TargetsProtein E6

Therapy Area/IndicationsSquamous Intraepithelial LesionsPenile NeoplasmsVaginal Neoplasms +[8]

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusDiscontinued (Phase 2 Clinical)

Highest Status in ChinaN/A

Originator CompaniesKite Pharma National Cancer Institute

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesKite Pharma National Cancer Institute

Active IndicationsN/A

Inactive IndicationsSquamous Intraepithelial LesionsPenile NeoplasmsVaginal Neoplasms +[8]

Other Information

ATC CodeN/A